Summer 2013

home / publications / contemporary-oncology / summer-2013
Impact of Molecular Testing on First-Line Treatment Decisions in NSCLC

Impact of Molecular Testing on First-Line Treatment Decisions in NSCLC

Onclive Team
October 18th 2013
Article

Five lung cancer experts discuss recent advances and current issues surrounding the treatment of non-small cell lung cancer

Novel Proteasome Inhibitors for Multiple Myeloma

Novel Proteasome Inhibitors for Multiple Myeloma

Vinay Gupta, MD;Wilson I. Gonsalves, MD;Shaji K. Kumar, MD
October 17th 2013
Article

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors

Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors

Cristina M. Almeida, MD, MPH;Michael A. Rodriguez, MD, MPH;Samuel Skootsky, MD;Janet Pregler, MD;Neil Steers, PhD;Neil S. Wenger, MD, MPH
October 11th 2013
Article

For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.